Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XTL Biopharmaceuticals has begun dosing patients in a phase I clinical trial of XTL-2125 for the treatment of chronic hepatitis C.
Subscribe to our email newsletter
The phase I trial is a placebo controlled, randomized, dose escalating study, which will evaluate the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125.
The study will enroll 48 patients into 6 cohorts comprised of 8 patients each of which 2 are placebo patients. Each patient will receive a single dose, followed by a 14-day multi-dosing regimen commencing one week after the single dose administration.
XTL-2125 is an oral non-nucleoside hepatitis C virus polymerase inhibitor. In preclinical studies, XTL-2125 has demonstrated robust activity against the hepatitis C virus in both cell-based and in-vivo systems. In addition, the drug has demonstrated a good safety profile in multiple animal species.
“XTLbio is in the unique position of having 2 novel compounds – XTL-2125 and XTL-6865 – in clinical trials in patients with chronic hepatitis C. We look forward to generating antiviral activity data from both studies over the next 12 months,” commented Ron Bentsur, XTLbio’s CEO.